Hot Keywords
Biomarker Discovery Autophagy and Cancer Breast Cancer Metastasis Brain Metastases Gastric Cancer Metastasis Lung Cancer Genetic Heterogeneity Colorectal Cancer Prostate Cancer Cancer Immunotherapy Circulating Tumor Cells Neuroendocrine Tumors

Top

Estimated Impact Factor in 2020: 2.01

Published on: 12 Jan 2021 Viewed: 432

Since launched in April 2015, under the guidance of the Editor-in-Chief Dr. Lucio Miele, Journal of Cancer Metastasis and Treatment (JCMT) has always been adhering to the principle of high-quality publication, exploring innovative academic topics and making every effort to publish valuable academic findings. Thus, we have gained trust and support from more and more famous researchers in this field, who are willing to join and contribute to JCMT. Though as of 31st December 2020, JCMT has not been indexed in important databases such as PubMed, Scopus and Emerging Sources Citation Index (ESCI), in 2020, the total citations of papers published in 2018 and 2019 were 243 times, and the total number of reviews and original articles published was 121. The estimated impact factor is 2.01. Click the link for details of the citations of JCMThttps://oaepublishstorage.blob.core.windows.net/jcmtuploadedfiles/Citations of JCMT as of Dec. 31 2020.xlsx

In 2021, we will complete the database (PubMed, Scopus and ESCI) application work. We believe that based on the strict quality control in the early stage and the support of experts in the field, JCMT will make a breakthrough in database application. We also believe that after JCMT is indexed in the database, as the exposure increases, it can achieve the first targeted impact factor of 5. At the beginning of the new year of 2021, the Editorial Office would like to express our sincere gratitude again to all Editorial Board members, guest editors, authors, readers and reviewers. We believe that in the near future, JCMT will become a leading journal in the field.


Copyright © 2021 OAE Publishing Inc. All Rights Reserved.